Correlation Between Halozyme Therapeutics and Alnylam Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Halozyme Therapeutics and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Alnylam Pharmaceuticals.
Diversification Opportunities for Halozyme Therapeutics and Alnylam Pharmaceuticals
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Halozyme and Alnylam is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Alnylam Pharmaceuticals go up and down completely randomly.
Pair Corralation between Halozyme Therapeutics and Alnylam Pharmaceuticals
Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 1.56 times less return on investment than Alnylam Pharmaceuticals. But when comparing it to its historical volatility, Halozyme Therapeutics is 1.04 times less risky than Alnylam Pharmaceuticals. It trades about 0.03 of its potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 19,986 in Alnylam Pharmaceuticals on November 9, 2024 and sell it today you would earn a total of 7,839 from holding Alnylam Pharmaceuticals or generate 39.22% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Halozyme Therapeutics vs. Alnylam Pharmaceuticals
Performance |
| Timeline |
| Halozyme Therapeutics |
| Alnylam Pharmaceuticals |
Halozyme Therapeutics and Alnylam Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Halozyme Therapeutics and Alnylam Pharmaceuticals
The main advantage of trading using opposite Halozyme Therapeutics and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Complementary Tools
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |